Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUC1-Activated T Cells in Relapsed/Resistant Ovarian Cancer
NCT06483048Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Sep 2024
- Primary completion
- Sep 2028
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous MUC1-activated T-cells in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Mayo Clinic. Primary endpoints: Dose-limiting toxicities at 28 days, Maximum tolerated dose at 28 days and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
autologous MUC1-activated T-cells
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06483048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06483048.